October 2, 2014 Australia is a powerhouse for medical science innovations, and nobody understands that better than Scott Power of Morgans Financial Ltd. Power watched the weaker Australian firms go the way of the dodo bird during the downturn in the biotech sector earlier this year, leaving only the fittest for investors to choose from. In this interview with The Life Sciences Report, he identifies a promising selection of survivors-biotechs with the power to rejuvenate an evolving portfolio.
http://ift.tt/1r3rs9I
http://ift.tt/1r3rs9I
No comments:
Post a Comment